Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 1/20 | 0.51 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.48 |
| ▸ | RUVBL1 | Q9Y265 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 2/20 | 0.46 |
| ▸ | GHSR | Q92847 | 2/20 | 0.46 |
| ▸ | MC5R | P33032 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888144 | 0.90 | UTS2R (0.47) | BDKRB2UTS2RRUVBL1GHSR | |
| SCHEMBL4888152 | 0.84 | MME (0.49) | BDKRB2UTS2RRUVBL1GHSR | |
| Hydrochloric Acid SCHEMBL6287792 | 0.83 | RUVBL1 (0.54) | UTS2RRUVBL1LMNAHTTKMT2A | |
| Hydrochloric Acid SCHEMBL6290405 | 0.83 | RUVBL1 (0.54) | UTS2RRUVBL1LMNAHTTKMT2A | |
| SCHEMBL14111057 | 0.82 | GHSR (0.46) | MC4RGHSRMC5RMC3R | |
| SCHEMBL4885609 | 0.79 | CPB2 (0.51) | BDKRB2 | |
| SCHEMBL4886971 | 0.79 | CHRNB2 (0.52) | BDKRB2 | |
| SCHEMBL29603261 | 0.78 | KDM4E (0.59) | UTS2RLMNAKMT2AMC4RGHSR | |
| SCHEMBL1387764 | 0.78 | KDM4E (0.61) | LMNAKMT2AMC4RGHSRMC5R | |
| SCHEMBL14906252 | 0.78 | KDM4E (0.61) | LMNAKMT2AMC4RGHSRMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | BDKRB2 3972/4885UTS2R 2145/4885RUVBL1 1245/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | BDKRB2 4288/4885UTS2R 4276/4885RUVBL1 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.